Table S1. STROBE statement—checklist of items that should be included in reports of cohort studies.

Item detail	Item no.	Recommendation	Reported on page#
Title and abstract	1	Indicate the study’s design with a commonly used term in the title or the abstract	416
		Provide in the abstract an informative and balanced summary of what was done and what was found	416
Introduction
Background/rationale	2	Explain the scientific background and rationale for the investigation being reported	417
Objectives	3	State specific objectives, including any prespecified hypotheses	417
Methods
Study design	4	Present key elements of study design early in the paper	417
Setting	5	Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection	417
Participants	6	Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up	417
		For matched studies, give matching criteria and number of exposed and unexposed
Variables	7	Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable	418
Data sources/measurement	8*	For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group	418
Bias	9	Describe any efforts to address potential sources of bias	418–420
Study size	10	Explain how the study size was arrived at	417–419 (Figure 1)
Quantitative variables	11	Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why	418, 419 (Figure 1)
Statistical methods	12	Describe all statistical methods, including those used to control for confounding	419, 420
		Describe any methods used to examine subgroups and interactions
		Explain how missing data were addressed
		If applicable, explain how loss to follow-up was addressed
		Describe any sensitivity analyses
Results
Participants	13*	Report numbers of individuals at each stage of study—e.g., numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	420, 423 (Figure 2)
		Give reasons for non-participation at each stage
		Consider use of a flow diagram
Descriptive data	14*	Give characteristics of study participants (e.g., demographic, clinical, social) and information on exposures and potential confounders	420–422 (Table 1)
		Indicate number of participants with missing data for each variable of interest
		Summarise follow-up time (e.g., average and total amount)
Outcome data	15*	Report numbers of outcome events or summary measures over time	420–423, 426, 427 (Tables 1–3)
Main results	16	Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (e.g., 95% CI). Make clear which confounders were adjusted for and why they were included	420, 423, 424 (Figures 3–5), 421, 422, 426, 427 (Tables 1–3)
		Report category boundaries when continuous variables were categorized
		If relevant, consider translating estimates of relative risk into absolute risk for a meaningful time period
Other analyses	17	Report other analyses done—e.g., analyses of subgroups and interactions, and sensitivity analyses	424, 425, 428 (Tables 4,5)
Discussion
Key results	18	Summarise key results with reference to study objectives	425
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or imprecision. Discuss both direction and magnitude of any potential bias	429, 430
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations, multiplicity of analyses, results from similar studies, and other relevant evidence	425, 428, 429
Generalisability	21	Discuss the generalisability (external validity) of the study results	429
Other information
Funding	22	Give the source of funding and the role of the funders for the present study and, if applicable, for the original study on which the present article is based	430

*, give information separately for exposed and unexposed groups; CI, confidence interval. An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at http://www.strobe-statement.org.